Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole + minocycline + amoxicillin + colloidal bismuth pectin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Drug Delivery Systems
- Administration
- Oral
01
Overview
This drug is a fixed-dose combination regimen consisting of four active pharmaceutical ingredients: rabeprazole (a proton pump inhibitor), minocycline (a tetracycline-class antibiotic), amoxicillin (a penicillin-class antibiotic), and colloidal bismuth pectin (a gastroprotective agent). It is used as a first-line or second-line treatment for Helicobacter pylori infection. The mechanism of action involves suppression of gastric acid secretion by rabeprazole to enhance the efficacy of antibiotics; direct antibacterial effects against H. pylori by minocycline and amoxicillin; and mucosal protection plus additional antimicrobial activity from colloidal bismuth pectin. This combination aims to overcome resistance issues associated with other regimens, especially in regions where tetracycline or metronidazole are less available or have higher resistance rates. Clinical studies have shown satisfactory eradication rates and good safety profiles for this regimen[1][6][2].
- Other names
- rabeprazole/minocycline/amoxicillin/bismuth quadruple therapyRMAB therapyminocycline/amoxicillin-based bismuth quadruple therapy
02
Targets
Bacterial RibosomeATP4A (Potassium–transporting ATPase alpha chain 1)NeuraminidasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on rabeprazole + minocycline + amoxicillin + colloidal bismuth pectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole + minocycline + amoxicillin + colloidal bismuth pectin.